

with liver disease, issues in long-term care of liver transplant recipients, management of autoimmune cholestatic liver disease, and current status of hepatitis vaccination and prophylaxis, to name a few.

Obesity has devastating effects on a patient's overall health, with specific negative effects on organ systems, long-term. The hepatologist must often manage diseases of the liver and pancreas as a result of obesity. This issue will provide a current update on the diagnosis, treatment, and management of NAFLD and NASH. Dr. Bernstein has assembled the top leaders in the field to provide timely clinical reviews. Articles are devoted to the following topics: Clinical and economic burden of NAFLD/NASH; NAFLD/NASH in children and its implications; Natural history of NAFLD/NASH; Diagnosis and evaluation of NAFLD/NASH; Radiological imaging in NAFLD/NASH; The use of liver biopsy in NAFLD: When to biopsy and in whom; Pathophysiology of NAFLD/NASH; Risk factors for the development of NAFLD/NASH including genetics; Role of intestinal microbes in NAFLD/NASH; NAFLD/NASH and the metabolic syndrome; NAFLD/NASH and lipid and insulin resistance; NAFLD/NASH and cardiac disease; Current treatment of NAFLD/NASH; Emerging treatment of NAFLD/NASH; NAFLD/NASH and HCC and NAFLD/NASH and liver transplantation. Readers will have a clear understanding of how to manage outcomes for these patients.

Dr. Rustgi has assembled the leading experts in the management of Hepatitis B to present the current treatment and clinical course for diagnosis and management of the disease. Articles are devoted to: Drug metabolism in the liver; Mechanism of Liver Damage including the RUCAM scale; Drug-induced acute liver failure; Epidemiology and genetic risk factors; Adverse drug reactions: type A (intrinsic or pharmacological) or type B (idiosyncratic); Pathology of injury including phenotypes; The clinical course of drug-induced liver disease; Environmental factors of drug hepatotoxicity; Newer agents in drug hepatotoxicity; Drug hepatotoxicity: herbal products; Drug hepatotoxicity: models including "human on a chip and zebrafish; Acute and chronic liver failure from drugs: impact on the kidney; and Management of acute hepatotoxicity including medical agents and liver support systems. Readers will come away with the cutting edge science behind the latest innovations in the treatment of Hepatitis B.

Dr. Brown provides a timely update on the clinical diagnosis and management of Hepatic Encephalopathy. His issue addresses current hot topics including Role of NH₄ in Pathogenesis of Hepatic Encephalopathy; How to diagnose and manage HE in fulminant hepatic failure;? New methods of Brain Imaging and testing (eg PET) and Hepatic Encephalopathy; Management New agents for HE (focus on NH₄ lowering drugs used in UCD); Legal responsibility of MD when he diagnoses HE; Diets in Encephalopathy; and Neurological manifestations of HE.

Copyright code : b1ff0b49e75ba280b9adc5e5079e4371